Chardan’s 1st Annual Microbiome Summit

March 07, 2019 | 7:30AM-6:00PM | Taylor Feehley, PhD
New York City

Summary of the Conference:

2019 has the potential to be a significant year for microbiome medicines with numerous trial initiations and multiple important data readouts throughout the year. This event will feature key public and private companies leading development efforts in this field and will cover a variety of approaches to therapeutically targeting the microbiome, both “bugs as drugs” and beyond. The 1st Annual Chardan Microbiome Medicines Summit will help investors begin to navigate this emerging space and provide insight into what is on the horizon for these novel therapeutics.

Date & Location:
Thursday, March 7, 2019
7:30AM – 6:00PM
Harvard Club - NYC
35 W 44th Street, 3rd Floor
New York, NY 10036

Lunch Panel: An Eye on the Prize: Regulatory and Other Key Considerations for the Development of Microbiome Medicines
Richard Andrew, President & CEO | Azitra, Inc. (Private)
Aoife Brennan, MB, ChB, President, CEO & CMO | Synlogic (SYBX)
Kevin Horgan, MD, CMO | Seres Therapeutics (MCRB)
Johanna Sandlund, MD, PhD, Medical Director | Singulex (Private)
Jonathan Solomon, CEO | BiomX (Private)

Confirmed Companies as of 3/4/19
4D Pharma plc (DDDD.LN)
Azitra, Inc. (Private)
BiomX (Private)
Caribou Bio (Private)
Evolve BioSystems (Private)
Finch Therapeutics (Private)
MaaT Pharma (Private)
Seres Therapeutics (MCRB)
Singulex (Private)
Siolta Therapeutics (Private)
Synlogic (SYBX)
uBiome (Private)
Vedanta Bio (Private)

Thank You!

We've received your information, and we're processing your request.

Get In Touch

17 State Street
Suite 2100
New York, NY 10004

+1 646-465-9001

All fields required